← brief for 2026-08-18 · Slowing decline

Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis.

Article B Peer reviewed Small trial

Key takeaways

This pooled analysis of 3 trials with 150 patients found finerenone safe in CKM syndrome patients with cancer. It showed no increase in cancer risk or death.

Who did this work

Ruppert M · Vaduganathan M · Claggett BL · Desai AS · Jhund PS · Henderson A · Lay-Flurrie J · Brinker M · Hofmeister L · Anker MS · Lam CSP · Senni M

Source

Article · PubMed, the drug frontier · 2026 Aug 18
https://pubmed.ncbi.nlm.nih.gov/42610431/